GlobeNewswire

Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
22/07/2026
AGOURA HILLS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the [...]
Specialized Manufacturing Capability Emerges as the New Competitive Advantage in the $23.2 Billion Global Biologics CDMO Market, Finds Alira Health
22/07/2026
Annual report examines how specialized manufacturing capabilities, investment, and M&A are reshaping the global biologics contract manufacturing landscape FRAMINGHAM, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Alira [...]
Traferox Technologies Receives FDA Premarket Approval for the TorEx Lung Perfusion System
22/07/2026
MISSISSAUGA, Ontario, July 22, 2026 (GLOBE NEWSWIRE) -- Traferox Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the TorEx ® Lung Perfusion [...]
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
22/07/2026
Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform Watch the “What This Means” video [...]
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
22/07/2026
Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect [...]
Exubrion Therapeutics Promotes Gregory Taglialatela to Chief Commercial Officer
22/07/2026
ATLANTA, July 22, 2026 (GLOBE NEWSWIRE) -- Exubrion Therapeutics ® , the company behind Synovetin OA ® , has promoted Gregory Taglialatela, MBA, to Chief Commercial Officer, effective July 1, 2026. In his new role, [...]
Med X Holdings Announces Official Name Change to Dazed Inc. and New Ticker Symbol "DAZD"
22/07/2026
Welcome to Dazed Inc. Austin, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Med X Holdings Announces Official Name Change to Dazed Inc. and New Ticker Symbol "DAZD" AUSTIN, Texas – July 21, 2026 – Med X [...]
Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies
22/07/2026
ALEXANDRIA, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Pfizer’s SmartDose medications arrive pre-tagged and pre-associated for use with KitCheck, reducing manual tagging labor as part of RFID inventory management workflows [...]
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
22/07/2026
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A [...]
uniQure to Announce Second Quarter 2026 Financial Results
22/07/2026
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing [...]
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
22/07/2026
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with [...]
BioCryst to Report Second Quarter 2026 Financial Results on August 5
22/07/2026
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5 [...]
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose- [...]
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
22/07/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) [...]
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close [...]
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
22/07/2026
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
22/07/2026
WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
22/07/2026
New AMA Category III codes, effective July 1, 2026, support the development of future reimbursement pathways for temporary transvenous diaphragm neurostimulation EXTON, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Lungpacer [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum